Fact sheet: Pictet Biotech

Fund information
Fund name
Pictet Biotech I dy GBP
Fund manager company
Pictet Asset Management (Europ
Fund type
Offshore Fund
Fund managers
  • Tazio Stornisince 26/05/2016
  • Lydia Hauetersince 26/05/2016
Fund objective
The sub-fund seeks capital growth by investing at least two-thirds of its total assets in the shares of particularly innovative companies operating in medical biotechnology. The investment universe is not restricted to a specific geographical zone. However, given the particularly innovative nature of the pharmaceutical industry in North America and Europe, the vast majority of investments will be made in this zone.
Benchmark
  • MSCI World
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
23.3%
1 Year rank in sector
-
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.21%
Fund size
£1,309m (£1,156m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
202
Top in this sector
Fund name1 Year
Pictet Biotech23.3%
Polar Capital Biotechnology22.4%
BB Medtech18%
Variopartner SICAV SeBiOpp18%
Fidelity Gbl Health Care16.6%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA92.4%
    Ireland3.5%
    Spain1.8%
    UK0.9%
    Belgium0.7%
  • Health Care54.7%
    Pharmaceuticals23.4%
    Technology13.1%
    Services8.4%
    Money Market0.4%
  • US Equities92.4%
    Irish Equities3.5%
    Spanish Equities1.8%
    UK Equities0.9%
    Belgian Equities0.7%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund-0.5%6.9%9.6%23.3%68.4%160.6%
Sector1.1%8.1%10.4%10.1%34.9%104.6%
Rank within sector------
Quartile
Calendar performance
 YTD - 20172016201520142013
Fund10.7%-8.6%18%31.8%52.6%
Sector10.6%-9.9%7.2%28.1%41%
Rank within sector-----
Quartile
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
3.86
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.34
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.5
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
23.32
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
11.47
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.5
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.81
Price movement
52 week high623.02
52 week low428.47
Current bid price-
Current offer price-
Current mid price581.03
Region
1USA92.4%
2Ireland3.5%
3Spain1.8%
4UK0.9%
5Belgium0.7%
6Money Market0.4%
7Switzerland0.3%
Industry sector
1Health Care54.7%
2Pharmaceuticals23.4%
3Technology13.1%
4Services8.4%
5Money Market0.4%
Asset type
1US Equities92.4%
2Irish Equities3.5%
3Spanish Equities1.8%
4UK Equities0.9%
5Belgian Equities0.7%
6Money Market0.4%
7Swiss Equities0.3%
Individual holdings
1CELGENE CORP9.5%
2AMGEN INC6.5%
3BIOGEN INC5.7%
4VERTEX PHARMACEUTICAL5.7%
5REGENERON PHARMACEUTICALS INC5.6%
6INCYTE CORP4.8%
7GILEAD SCIENCES INC4.3%
8BIOMARIN PHARMACEUTICAL3.8%
9ALEXION PHARMACEUTICALS INC3.7%
Management
Fund manager group
Pictet
Fund manager company
Pictet Asset Management (Europ
Fund type
Offshore Fund
Fund objective
The sub-fund seeks capital growth by investing at least two-thirds of its total assets in the shares of particularly innovative companies operating in medical biotechnology. The investment universe is not restricted to a specific geographical zone. However, given the particularly innovative nature of the pharmaceutical industry in North America and Europe, the vast majority of investments will be made in this zone.
Benchmark
  • MSCI World
Investment style
Growth
Investment method
Shares
Fund managers
NameSinceBiography
Tazio Storni26/05/2016Tazio Storni joined Pictet Asset Management in October 2014 as a Senior Investment Manager in the Sector & Theme Funds team. He began his investment career in 2005 with UBS Global Asset Management, as a financial analyst covering Biotech, Medtech and Chemical companies. In 2010 he took over the responsibility for the UBS (Lux) Equity Health Care fund. Prior to joining Pictet Asset Management Tazio worked for Bellevue Asset Management as lead portfolio manager on the BB Biotech (Lux) Fund. He holds a Masters in Biology and a PhD in Immunology from the Eidgenössische Technishe Horchschule in Zurich (ETH). Tazio is a Chartered Financial Analyst (CFA) charterholder.
Lydia Haueter26/05/2016
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, IA Recognised, Reporting Fund Status, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Belgium, Switzerland, Chile, Cyprus, Germany, Spain, Finland, France, United Kingdom, Greece, Italy, Liechtenstein, Luxembourg, Netherlands, Norway, Offshore, Peru, Portugal, Singapore, Sweden, Taiwan - Province Of China
Pictet Biotech HI EUR
Initial charge5%
Annual charge0.8%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.26%
Total expense ratio (TER)1.22%
Bid price-
Offer price-
Mid price484.07
CurrencyEUR
Price updated26/04/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeB8W7
Pictet Biotech HP CHF
Initial charge5%
Annual charge1.6%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.05%
Total expense ratio (TER)2.01%
Bid price-
Offer price-
Mid price588.36
CurrencyCHF
Price updated26/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeF32P
Pictet Biotech HP EUR
Initial charge5%
Annual charge1.6%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.05%
Total expense ratio (TER)2.01%
Bid price-
Offer price-
Mid price478.18
CurrencyEUR
Price updated26/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeO915
Pictet Biotech HR EUR
Initial charge5%
Annual charge2.3%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.75%
Total expense ratio (TER)2.71%
Bid price-
Offer price-
Mid price430.52
CurrencyEUR
Price updated26/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeB8W8
Pictet Biotech I EUR
Initial charge5%
Annual charge0.8%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.21%
Total expense ratio (TER)1.16%
Bid price-
Offer price-
Mid price686.77
CurrencyEUR
Price updated26/04/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeO914
Pictet Biotech I USD
Initial charge5%
Annual charge0.8%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.2%
Total expense ratio (TER)1.16%
Bid price-
Offer price-
Mid price746.99
CurrencyUSD
Price updated26/04/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeXV18
Pictet Biotech I dy GBP
Initial charge5%
Annual charge0.8%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.21%
Total expense ratio (TER)1.14%
Bid price-
Offer price-
Mid price581.03
CurrencyGBP
Price updated26/04/2017
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeGLJ4
Pictet Biotech P EUR
Initial charge5%
Annual charge1.6%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2%
Total expense ratio (TER)1.96%
Bid price-
Offer price-
Mid price605.84
CurrencyEUR
Price updated26/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeO913
Pictet Biotech P USD
Initial charge5%
Annual charge1.6%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2%
Total expense ratio (TER)1.96%
Bid price-
Offer price-
Mid price658.93
CurrencyUSD
Price updated26/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeXV20
Pictet Biotech P dy GBP
Initial charge5%
Annual charge1.6%
Min single investment£10,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2%
Total expense ratio (TER)1.96%
Bid price-
Offer price-
Mid price512.33
CurrencyGBP
Price updated26/04/2017
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeBYQ8
Pictet Biotech P dy USD
Initial charge5%
Annual charge1.6%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2%
Total expense ratio (TER)1.96%
Bid price-
Offer price-
Mid price658.63
CurrencyUSD
Price updated26/04/2017
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeA1F4
Pictet Biotech R EUR
Initial charge5%
Annual charge2.3%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.7%
Total expense ratio (TER)2.66%
Bid price-
Offer price-
Mid price545.44
CurrencyEUR
Price updated26/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeO912
Pictet Biotech R USD
Initial charge5%
Annual charge2.3%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.7%
Total expense ratio (TER)2.66%
Bid price-
Offer price-
Mid price593.29
CurrencyUSD
Price updated26/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeXV46
Pictet Biotech Z USD
Initial charge5%
Annual charge-
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.35%
Total expense ratio (TER)0.32%
Bid price-
Offer price-
Mid price788.05
CurrencyUSD
Price updated26/04/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFOIN
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.